2-Hydroxyphenylmethylamine, hydrobromide | 209738-19-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Hydroxyphenylmethylamine, hydrobromide
• 英文别名: 2-(Aminomethyl)phenol hydrobromide；2-(aminomethyl)phenol;hydrobromide
• CAS: 209738-19-2
• 化学式: BrH*C₇H₉NO
• 分子量: 204.066
• InChiKey: PCQIFSMQGOYHCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.43
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  46.2
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  邻甲氧基苄胺 生成 2-Hydroxyphenylmethylamine, hydrobromide
  参考文献：
  名称：

  Triazolo[4,5-D]pyrimidinyl derivatives and their use as medicaments

  摘要：

  本发明涉及三唑并[4,5-d]嘧啶-3-基衍生物，该衍生物在治疗血小板聚集障碍方面具有用途。

  公开号：

  US06297232B1

文献信息

• Protein kinase modulators and methods of use
  申请人：Buhr A. Chris

  公开号：US20060211709A1

  公开（公告）日：2006-09-21

  Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.

  本发明揭示了替代芳基1,4-吡嗪衍生物及其在治疗焦虑症、抑郁症和与压力相关的疾病中的应用。
• PROTEIN KINASE MODULATORS AND METHODS OF USE
  申请人：Exelixis, Inc.

  公开号：EP1501514A2

  公开（公告）日：2005-02-02
• EP1501514A4
  申请人：——

  公开号：EP1501514A4

  公开（公告）日：2009-08-26
• US7704995B2
  申请人：——

  公开号：US7704995B2

  公开（公告）日：2010-04-27
• [EN] PROTEIN KINASE MODULATORS AND METHODS OF USE<br/>[FR] MODULATEURS DE PROTEINE KINASE ET PROCEDES D'UTILISATION
  申请人：EXELIXIS INC

  公开号：WO2003093297A2

  公开（公告）日：2003-11-13

  This invention relates to compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compositions containing such compounds. Even more specifically, the invention relates to compounds that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Methods of therapeutically or prophylactically using the compounds and compositions to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amounts of such compounds.